Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players
India's pharmaceutical companies are expected to have a mixed performance in the upcoming September quarter.
Companies like Sun Pharmaceutical Industries and Aurobindo Pharma are likely to report good growth.
In contrast, Dr Reddy's Laboratories and Lupin may face challenges due to increased competition and a high base.
Pricing pressure and elevated raw material costs are also expected to impact overall performance.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on economictimes.indiatimes.com — the content belongs to The Economic Times.
